Altogether, these trials highlight the potential of dual GLP-1/glucagon receptor agonists in treating MASLD through complementary mechanisms that reduce liver fat, improve cardiometabolic markers, and address liver inflammation. The gene discussed is GCGR; the disease is metabolic dysfunction-associated steatotic liver disease.